Drug Evaluation of Degu Insulin in the Treatment of Type 1 and Type 2 Diabetes Mellitus
Degu insulin (IDeg) is a new generation of basic insulin, which has a long lasting effect. The pharmacokinetic and pharmacodynamic data of Degu insulin were discussed in order to investigate the efficacy of Degu insulin in the treatment of type 1 and type 2 diabetes mellitus. Cross-study standardized methods were used to collect and analyze blood and normal glucose clamp technique to achieve cross-study evaluation of pharmacokinetic and pharmacodynamic parameters. The data showed that the half-life of IDeg was > 25 h, and reached a stable state within 3 days after administration in all study groups. The pharmacokinetic characteristics of IDeg indicated a uniform distribution within a given interval. The pharmacodynamic curve of IDeg is flat and stable, which is proved by the effect of reducing glucose uniformly distributed in all four and six hours during 24 hours. These characteristics have been consistently confirmed in different groups of type 1 and type 2 diabetes, including men and women of different races (type 2 diabetes), the elderly and patients with liver or kidney injury. IDeg has an ultra-long duration of more than 42 hours, and the variability of glucose reduction in daily subjects is reduced by four times.